Solving the
Immunogenicity Challenge
Unlocking the Full Potential of Biologic Therapies
The Challenge
Biotherapeutics face a critical obstacle: the human immune system’s natural response to foreign molecules.
This response produces anti-drug antibodies (ADAs) that can reduce efficacy by limiting exposure, hindering therapeutic activity, and triggering unintended immune reactions.
Our Solution
ADAXION is advancing best-in-class biologics deimmunized with our ADAx platform
Our platform enables biotherapeutics that would otherwise have prohibitive immunogenicity, driven by a drug’s pharmacology or its intrinsic foreignness.
ADAx Platform
Our novel ADAx platform technology incorporates proprietary CD22 ligands on the biologic to actively eliminate therapeutic-specific B cells while maintaining full functionality.
Our Pipeline
ADAXION’s technology is designed to enable the development of novel biologic therapies that overcome immunogenicity limitations.